Immunome (IMNM) Competitors

IGM Biosciences (NASDAQ:IGMS) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations.

Which has preferable earnings and valuation, IGMS or IMNM?

Immunome has higher revenue and earnings than IGM Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IGM Biosciences	$2.13M	263.74	-$246.42M	-$3.64	-2.60
Immunome	$10.78M	55.16	-$106.81M	-$8.11	-1.22

Do analysts prefer IGMS or IMNM?

IGM Biosciences presently has a consensus price target of $16.13, suggesting a potential upside of 70.27%. Immunome has a consensus price target of $28.83, suggesting a potential upside of 191.10%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than IGM Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IGM Biosciences	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Immunome	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is IGMS or IMNM more profitable?

Immunome has a net margin of -3,014.59% compared to IGM Biosciences' net margin of -7,534.03%. Immunome's return on equity of -48.36% beat IGM Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IGM Biosciences	-7,534.03%	-155.42%	-61.04%
Immunome	-3,014.59%	-48.36%	-41.71%

Does the MarketBeat Community favor IGMS or IMNM?

IGM Biosciences received 40 more outperform votes than Immunome when rated by MarketBeat users. However, 73.81% of users gave Immunome an outperform vote while only 50.35% of users gave IGM Biosciences an outperform vote.

Company	Underperform	Outperform
IGM Biosciences	Outperform Votes 71 50.35%	Underperform Votes 70 49.65%
Immunome	Outperform Votes 31 73.81%	Underperform Votes 11 26.19%

Does the media refer more to IGMS or IMNM?

In the previous week, Immunome had 2 more articles in the media than IGM Biosciences. MarketBeat recorded 9 mentions for Immunome and 7 mentions for IGM Biosciences. IGM Biosciences' average media sentiment score of 0.11 beat Immunome's score of -0.09 indicating that IGM Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IGM Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, IGMS or IMNM?

IGM Biosciences has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Do insiders & institutionals believe in IGMS or IMNM?

42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by company insiders. Comparatively, 8.6% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Immunome beats IGM Biosciences on 13 of the 18 factors compared between the two stocks.